Preston D Moore
Overview
Explore the profile of Preston D Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Defoe D, Rao H, Harris 3rd D, Moore P, Brocher J, Harrison T
PLoS One
. 2020 Jan;
15(1):e0226725.
PMID: 31929545
The cell cycle regulator p27Kip1 is a critical factor controlling cell number in many lineages. While its anti-proliferative effects are well-established, the extent to which this is a result of...
2.
Hanker A, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, et al.
Clin Cancer Res
. 2019 Feb;
25(4):1434.
PMID: 30770493
No abstract available.
3.
Jansen V, Bhola N, Bauer J, Formisano L, Lee K, Hutchinson K, et al.
Cancer Res
. 2019 Feb;
79(4):874.
PMID: 30770369
No abstract available.
4.
Hanker A, Estrada M, Bianchini G, Moore P, Zhao J, Cheng F, et al.
Cancer Res
. 2019 Feb;
79(4):873.
PMID: 30770368
No abstract available.
5.
Hanker A, Estrada M, Bianchini G, Moore P, Zhao J, Cheng F, et al.
Cancer Res
. 2017 Apr;
77(12):3280-3292.
PMID: 28396358
mutations are associated with resistance to HER2-targeted therapies. We previously showed that transgenic mammary tumors are resistant to the HER2 antibodies trastuzumab and pertuzumab but respond to PI3K inhibitor buparlisib...
6.
Hanker A, Garrett J, Estrada M, Moore P, Ericsson P, Koch J, et al.
Clin Cancer Res
. 2017 Apr;
23(15):4323-4334.
PMID: 28381415
Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2) breast cancers escape from...
7.
Jansen V, Bhola N, Bauer J, Formisano L, Lee K, Hutchinson K, et al.
Cancer Res
. 2017 Mar;
77(9):2488-2499.
PMID: 28249908
Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet uncharacterized. In this study, we used a kinome-wide siRNA screen...
8.
Waddell A, Vallance J, Moore P, Hummel A, Wu D, Shanmukhappa S, et al.
Inflamm Bowel Dis
. 2015 Aug;
21(12):2737-46.
PMID: 26313694
Background: IL-33, a member of the IL-1 cytokine family that signals through ST2, is upregulated in ulcerative colitis (UC); however, the role of IL-33 in colitis remains unclear. IL-33 augments...
9.
Young C, Zimmerman L, Hoshino D, Formisano L, Hanker A, Gatza M, et al.
Mol Cell Proteomics
. 2015 May;
14(7):1959-76.
PMID: 25953087
Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K) have been shown to transform human mammary epithelial cells (MECs). These mutations are present in all...
10.
Balko J, Giltnane J, Wang K, Schwarz L, Young C, Cook R, et al.
Cancer Discov
. 2013 Dec;
4(2):232-45.
PMID: 24356096
Unlabelled: Neoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in approximately 30% of patients with triple-negative breast cancers (TNBC). In patients lacking a pCR, NAC selects a subpopulation of...